Allarity Therapeutics, Inc. (ALLR) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Allarity Therapeutics, Inc. (ALLR) closed at USD 0.83 on 2026-10-15, a change of -41.3 % over the past year, with a market capitalization of USD 14.24M.
Allarity Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 0.83 |
| 2026-10-14 | 0.87 |
| 2026-10-13 | 0.87 |
| 2026-10-12 | 0.86 |
| 2026-10-09 | 0.99 |
| 2026-10-08 | 0.98 |
| 2026-10-07 | 0.98 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Allarity Therapeutics, Inc. key figures
- Previous close
- USD 0.83 (2026-10-15)
- 1-year change
- -41.3 %
- Market cap
- USD 14.24M
- Enterprise value
- USD 19.54M
- P/E ratio (trailing)
- -1.13
- P/E ratio (forward)
- -1.04
- EPS (trailing)
- -0.79
- EPS (forward)
- -0.86
- PEG ratio
- n/a
- Price to book
- 4.03
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.94
- Employees
- 7
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Allarity Therapeutics, Inc. and compare it with other stocks.
Analyze ALLRAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Allarity Therapeutics, Inc. shares.